The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan

Table 3

Cox proportional hazard regression model of overall survival.

Characteristics	Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)
PLD group vs. epirubicin group	1.62 (0.84–3.11)	0.152	1.36 (0.69–2.68)	0.373
Pathologic complete response (pCR) vs. non-pCR	0.14 (0.02–1.04)	0.055	0.12 (0.02–0.88)	0.037
Matching criteria
Preoperative clinical stage (III vs. I-II)	1.75 (0.86–3.54)	0.121	0.78 (0.32–1.93)	0.596
Molecular subtype
Luminal type (Her2 negative)	1.00		1.00
Her2 positive	1.96 (0.91–4.23)	0.087	1.81 (0.8–4.13)	0.157
TNBC	3.14 (1.38–7.13)	0.006	2.25 (0.87–5.82)	0.096
Chemoregimen before surgery with taxane vs. without taxane	1.96 (0.91–4.23)	0.086	2.40 (1.09–5.25)	0.029
Histological grade (III vs. I-II)	3.95 (1.99–7.83)	<0.001	2.71 (1.28–5.76)	0.009
Age	1.04 (1.00–1.07)	0.063	1.01 (0.98–1.05)	0.532
Tumor size (mm)	1.02 (1.01–1.03)	<0.001	1.02 (1.01–1.03)	<0.001